Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 30, Issue 6, 2009, Pages 628-633

  Shah, Shailen ^a   Berger, William ^b   Lumry, William ^c   La Force, Craig ^d   Wheeler, William ^e   Sacks, Harry ^e  

^a Allergy and Asthma Consultants NJ/PA   (United States)

^b Allergy & Asthma Associates of Northern California   (United States)

^c Allergy And Asthma Research Associates Texas   (United States)

^d North Carolina Clinical Research   (United States)

^e Meda Pharmaceuticals Inc   (United States)

Author keywords

Allergic rhinitis; Antihistamine; Azelastine HCL; Clinical trial; Efficacy; Nasal congestion; Nasal spray; Rhinorrhea; Safety; Sneezing

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; NOSE SPRAY; PLACEBO;

ADOLESCENT; ADULT; AEROSOL; AGED; ARTICLE; BITTER TASTE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; EVENING DOSAGE; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NASAL PRURITUS; NOSE CONGESTION; NOSE DISEASE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RHINORRHEA; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SINUS HEADACHE; SNEEZING; SOMNOLENCE; TOTAL NASAL SYMPTOM SCORE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; CHILD; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; NASAL OBSTRUCTION; PHTHALAZINES; RHINITIS, ALLERGIC, SEASONAL; SNEEZING; TREATMENT OUTCOME;

EID: 73649121614     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3296     Document Type: Article

References (27)

1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3-9, 2007.
2. Rosenwasser LJ. Treatment of allergic rhinitis. Am J Med 113:17S-24S, 2002.
3. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008.
4. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 29:600-608, 2008.
5. Physician survey sponsored by the American College of Allergy, Asthma and Immunology. Rochester, NY: Harris Interactive, Inc., October 19-21, 2001.
6. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
7. Zechel HJ, Brock N, Lenke D, et al. Pharmacological and toxicological properties of azelastine, a novel antiallergic agent. Arzneimittelforschung 31:1184-1193, 1981.
8. Chand N, Pillar J, Nolan K, et al. Inhibition of allergic and nonallergic leukotriene C4 formation and histamine secretion by azelastine: Implication for its mechanism of action. Int Arch Allergy Appl Immunol 90:67-70, 1989.
9. Hamasaki Y, Shafigeh M, Yamamoto S, et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 76:469-475, 1996.
10. Nieber K, Baumgarten C, Rathsack R, et al. Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy 23:69-71, 1993.
11. Shinoda M, Watanabe N, Suko T, et al. Effects of anti-allergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions. Am J Rhinol 11:237-241, 1997.
12. Ito H, Nakamura Y, Takagi S, et al. Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforschung 48:1143-1147, 1998.
13. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity. J Allergy Clin Immunol 98:1088-1096, 1996.
14. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J 73:382-386, 1994.
15. Ratner PH, Findlay SR, Hampel F Jr, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 94:818-825, 1994.
16. Banov CH, and Lieberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol 86:28-35, 2001.
17. Juniper EF, Thompson AK, Ferrie PJ, et al. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104:364-369, 1999.
18. Juniper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98:843-845, 1996.
19. Berger WE, and White MV. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 91:205-211, 2003.
20. LaForce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 93:154-159, 2004.
21. Ratner PH, Hampel F, van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:74-81, 2008.
22. Berger W, Hampel F Jr, Bernstein J, et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 97:375-381, 2006.
23. Corren J, Storms W, Bernstein J, et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 27:543-553, 2005.
24. Lee TA, and Pickard AS. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy 27:852-859, 2007.
25. Portnoy JM, Van Osdol T, and Williams PB. Evidence-based strategies for treatment of allergic rhinitis. Curr Allergy Asthma Rep 4:439-446, 2004.
26. Bernstein JA, Prenner B, Ferguson BJ, et al. Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. Am J Rhinol Allergy 23:512-517, 2009.
27. van Bavel J, Howland WC, Amar NJ, et al. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 30:512-518, 2009.